Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCX 4251 Phase 2 Study in Acute Exacerbations of Blepharitis
NCT03926026Phase 2Completed
- Sponsor
- Nicox S.A.
- Start
- Mar 2019
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NCX 4251 in blepharitis (4 arms), sponsored by Nicox S.A. Primary endpoint: Composite (Sum) Score of Signs & Symptoms of Blepharitis at 14 days. Started Mar 2019; status: completed.
02
Drugs
NCX 4251
03
Conditions
blepharitis
Beyond the preview
Go deeper on NCT03926026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926026.